A Daily Pill Restores Skin Color in Some Vitiligo Patients

Imagine looking in the mirror and finding the map of your skin subtly, but unmistakably, shifting: smooth patches of pale where color used to be. Vitiligo does that—steals pigment in blotches that can stretch across the face, hands and torso—and for many people the loss is far more than cosmetic. It changes how they are seen. It changes how they feel.

Now a tablet taken once a day has shown the ability to coax color back into those patches for a portion of patients. In two large, randomized trials published in The Lancet, researchers tested 15 mg of upadacitinib against placebo in 614 participants aged 12 and older across 138 centers in 18 countries. Patients had the most common form of vitiligo, with involvement of both face and body, and they took the drug or placebo every day for 48 weeks in a double-blind setup.

The headline numbers are straightforward and a little blunt: about a quarter of people on the pill recovered at least 75 percent of facial pigment by week 48, compared with roughly 6–7 percent on placebo. When the target is more modest—half the lost color across affected areas—roughly 19–21 percent of treated participants reached it, while only 6 percent in the placebo arms did. A smaller subset did exceptionally well: around 14 percent regained at least 90 percent of their facial color versus 2–3 percent with placebo.

A UV photograph of a hand with vitiligo. 

Those figures show promise, but they also show limits. Most patients did not reach the trial’s main repigmentation targets. And the drug’s effects were still accruing at week 48, suggesting that longer treatment might yield further gains. No one yet knows whether the regained pigment will persist after therapy stops.

How does the pill work? Upadacitinib belongs to the JAK inhibitor family and dials down an immune pathway that, in vitiligo, mistakenly attacks melanocytes—the cells that give skin its color. With the immune pressure eased, surviving pigment cells can repopulate the epidermis, or new pigment can be produced in areas that had lost it.

Because the medication circulates systemically, it avoids the practical problem of applying creams to hard-to-reach or widespread areas and could be a real convenience compared with repeated clinic trips for light therapy. The European Union has approved upadacitinib for eligible adults and adolescents 12 and older with this common form of vitiligo; other regions vary in their approvals.

In short: a daily 15 mg tablet produced meaningful repigmentation for a minority of patients and has become an approved option in the EU, but it is not a cure-all.

Safety questions remain. The most commonly reported side effects were upper respiratory infections, acne, headaches and inflammation of the nose and throat. Seven participants developed shingles; serious adverse events were reported in 4 percent of treated patients in the first trial and 2 percent in the second. Because JAK inhibitors have known associations—with serious infections, cardiovascular events, malignancies and blood clots when used for other indications—longer, larger studies are needed to clarify rare or late-emerging risks.

Interpretation of the trials also requires caution. The studies compared the pill to placebo, not to existing topical or light-based therapies, so direct comparisons of effectiveness and safety against standard care are still lacking. Most participants were White, leaving open questions about effectiveness and visibility of repigmentation in people with darker skin tones. And the research was funded and designed with involvement from AbbVie, the manufacturer of upadacitinib, a fact the authors acknowledge and regulators consider.

Participants continue to be followed for another 112 weeks; that extended follow-up will be crucial for understanding how much more repigmentation might occur, how durable it is, and who is most likely to benefit without undue risk. For now, upadacitinib offers a new tool: not a universal fix, but a systemic option that works for some people where topicals and light therapy are impractical. As the data mature, clinicians and patients will have clearer answers about when a daily pill makes sense alongside—or instead of—other treatments.